Sarcopenia in Axial and Peripheral Spondyloarthropathies

NCT03319264 | Completed

• 2 other identifiers: 69HCL17_01452017-A02391-52
• Study Type: interventional
• Target: 106
• Locations: 1 country
• Sites: 1

Brief Summary

Spondylarthropathies (SpA) are among the most common chronic inflammatory rheumatisms in adults, responsible for a muscular loss or sarcopenia which can be very disabling, not much documented in the literature, and not yet studied in France. In addition, sarcopenia is associated with decreased physical activity and increased risk of falls and fractures. A better characterization of the determinants of this muscular loss will allow to better detect and take care of it. The aim is to conduct the first French study on the prevalence and severity of sarcopenia in patients with spondyloarthropathies and to study the variables that may be associated with it. Finally, we propose to evaluate obesity related to sarcopenia in these patients and compare them to cases matched for age and sex (from OFELY / STRAMBO cohorts, Lyon, FRANCE). This is a prospective interventional and monocentric study with minimal risks and constraints: patients will be included for one day for an evaluation of their sarcopenia by measuring their muscle strength, physical performance and body composition and recording of their socio-demographic and disease characteristics.

Conditions

Spondylarthropathy; Sarcopenia

Keywords

Spondylarthropathy; Sarcopenia; lean mass; fat mass

Outcome Measures

Primary Outcomes (3)

• Muscular strength

  Muscular strength is the first outcome to evaluate sarcopenia

  At day 1

• Walking speed

  Walking speed is a physical performance outcome, that is the second outcome to evaluate sarcopenia

  At day 1

• Muscular mass

  Muscular mass is the third outcome to evaluate sarcopenia and will be assessed using DXA

  Up to 4 month after inclusion

Secondary Outcomes (6)

• Alcohol consumption

  At day 1

• Tobacco consumption

  At day 1

• Time of sport practice per month

  At day 1

• Physical activity rate in work

  At day 1

• Average walking time in a week

  At day 1

Study Arms (1)

Patients with SpA

EXPERIMENTAL

Patients included in this single group study will have 3 interventions to assess the severity of muscle loss : * dynamometry exam * walking test * Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia \& Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire.

Other: Dynamometry exam; Other: Walking test; Radiation: DXA measurement; Other: SARQOL questionnaire; Behavioral: Life habits Questionnaire

Interventions

Walking test OTHER

A 4 metres walking test will be performed to assess patient's walking speed

Patients with SpA

DXA measurement RADIATION

DXA measurement will be performed to assess patient's body composition

Patients with SpA

SARQOL questionnaire OTHER

Patient's quality of life will be assessed thanks to the SARQOL questionnaire

Patients with SpA

Dynamometry exam OTHER

Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength

Patients with SpA

Life habits Questionnaire BEHAVIORAL

Life habits Questionnaire

Patients with SpA

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women, 18 to 80 years old
• Hospitalized or attending the rheumatology department for spondyloarthopathy.

You may not qualify if:

• no signed consent
• Immobilization for a period of more than 15 days during the last 3 months
• pregnant or breastfeeding woman
• Not affiliated to the national healthcare insurance
• difficulty in understanding French
• psychiatric disorder

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Service de Rhumatologie - Hôpital Edouard Herriot

Lyon, 69003, France

Location

Related Publications (1)

• Merle B, Cottard M, Sornay-Rendu E, Szulc P, Chapurlat R. Spondyloarthritis and Sarcopenia: Prevalence of Probable Sarcopenia and its Impact on Disease Burden: The Saspar Study. Calcif Tissue Int. 2023 Jun;112(6):647-655. doi: 10.1007/s00223-023-01074-3. Epub 2023 Mar 21.

  PMID: 36944706 RESULT

MeSH Terms

Conditions

Spondylarthropathies; Sarcopenia

Condition Hierarchy (Ancestors)

Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 18, 2017
• First Posted: October 24, 2017
• Study Start: November 2, 2017
• Primary Completion: July 4, 2018
• Study Completion: July 4, 2018
• Last Updated: December 19, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)